현대에서의 생백신과 이에 대한 면역반응의 재평가
Reappraisal of Live Vaccines and Immunity in These Modern Days
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The vaccines has been developed over the first two hundred years since Jenner's smallpox vaccination. In modern days, vaccination has had the largest impact on the incidence and persistence of infections. Although natural infection induces lifelong immunity, the assumption that the vaccine also confers permanent protection has been reconsidered following outbreaks of measles in students who had been vaccinated 15-20 years prior to infection in the US in the 1980s. Clinical studies have proposed several mechanisms such as vaccine failure in some individuals and the subsequent loss of immunity after vaccination. An ideal vaccine is relatively easy to define, but few real vaccines approach the ideal. Many difficulties account for the failure in producing these ideal vaccines. However, recent advances in methods for studying immune response to pathogens have provided a better understanding of immune mechanisms. Based on these findings, the development of good vaccine formulations allowing stimulation of optimal and prolonged protective immunity and immunization policies or schedules should lead to the introduction of vaccines for previously resistant organisms.
Abstract
The vaccines has been developed over the first two hundred years since Jenner's smallpox vaccination. In modern days, vaccination has had the largest impact on the incidence and persistence of infections. Although natural infection induces lifelong immunity, the assumption that the vaccine also confers permanent protection has been reconsidered following outbreaks of measles in students who had been vaccinated 15-20 years prior to infection in the US in the 1980s. Clinical studies have proposed several mechanisms such as vaccine failure in some individuals and the subsequent loss of immunity after vaccination. An ideal vaccine is relatively easy to define, but few real vaccines approach the ideal. Many difficulties account for the failure in producing these ideal vaccines. However, recent advances in methods for studying immune response to pathogens have provided a better understanding of immune mechanisms. Based on these findings, the development of good vaccine formulations allowing stimulation of optimal and prolonged protective immunity and immunization policies or schedules should lead to the introduction of vaccines for previously resistant organisms.
참고문헌 (33)
- Plotkin SL, "A short history of vaccination. in: Vaccines. 4th ed", pp.1~16 (2004), WB Saunders Co
- Chen RT, "Measles antibodies: re-evaluation of protective titers", J Infect Dis, 162, pp.1036~1062 (1990)
- Gustafson TL, "Measles outbreak in a fully immunized secondary-school population", N Engl J Med, 316, pp.771~774 (1987)
- Whittle HC, "Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa", Lancet, 353, pp.98~102 (1999)
- Mossong J, "Modelling measles re-emergence as a result of waning of immunity in vaccinated opulation", Vaccine, 21, pp.4597~4603 (2003)
- Mossong J, "Modelling the impact of subclinical measles transmission in vaccinated populations with waning immunity", Am J Epidemiol, 150, pp.1238~1249 (1999)
- Rouderfer V, "Waning immunity and its effect on vaccination schedules", Math Biosci, 124, pp.59~82 (1994)
- Galazka AM, "Resurgence of diphtheria", Eur J Epidemiol, 11, pp.95~105 (1995)
- Teitelbaum MA, "Immunization and vaccine-preventable illness, United States, 1992-1997", Stat Bull Metrop Insur Co, 80, pp.13~20 (1997)
- Wright SW, "Pertussis infection in adults", South Med J, 91, pp.702~708 (1998)
- Whittle HC, "Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa", Lancet, 353, pp.98~102 (1999)
- Pelletier L, "benefit-cost analysis of two dose measles immunization in Canada", Vaccine, 16, pp.989~996 (1998)
- Janaszek W, "Measles vaccine efficacy during an epidemic in 1998 in the highly vaccinated population in Poland", Vaccine, 21, pp.4734~478 (2003)
- Wenger JD, "Haemophilus influenzae vaccine. 4th ed", pp.229~268 (2004), WB Saunders Co
- Amanna IJ, "Duration of humoral immunity to common viral and vaccine antigens", N Engl J Med, 357, pp.1903~1915 (2007)
- Plotkin SA, "Immunologic correlates of protection induced by vaccination", Pediatr Infect Dis J, 20, pp.63~75 (2001)
- Plotkin S, "Correlates of vaccine-induced immunity", Clin Infect Dis, 47, pp.401~ (2008)
- Onorato IM, "Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines", J Infect Dis, 163, pp.1~6 (1991)
- Plotkin SA, "Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge", J Infect Dis, 159, pp.860~865 (1989)
- Taranger J, "Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis", J Infect Dis, 181, pp.1010~1013 (2000)
- Chen RT, "Measles antibody: reevaluation of protective titers", J Infect Dis, 162, pp.1036~1042 (1990)
- Permar SR, "Role of CD8+ lymphocytes in control and clearance of measles virus infection of rhesus monkeys", J Virol, 77, pp.4396~4400 (2003)
- Permar SR, "Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys", J Infect Dis, 190, pp.998~1005 (2004)
- Pan CH, "Inaugural article: modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H encoding alphavirus replicon particles", Proc Natl Acad Sci USA, 통권 : 102, pp.11581~11588 (2005)
- Polack FP, "Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles", Nat Med, 6, pp.776~781 (2000)
- Plotkin SA, "Vaccination against the major infectious diseases", C R Acad Sci III, 322, pp.943~951 (1999)
- Kobiler D, "Protective antigen as a correlative marker for anthrax in animal models", Infect Immun, 74, pp.5871~5876 (2006)
- Pitt ML, "In vitro correlate of immunity in a rabbit model of inhalational anthrax", Vaccine, 19, pp.4768~4773 (2001)
- Reuveny S, "Search for correlates of protective immunity conferred by anthrax vaccine", Infect Immun, 69, pp.2888~2893 (2001)
- Hobson D, "The role of serum haemagglutination inhibiting antibody in protection against challenge infection with influenza A2 and B viruses", J Hyg, 70, pp.767~777 (1972)
- Lee H, "Immune response ininfants of the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A", Clin Vaccine Immunol, 16, pp.376~381 (2009)
- Horstmann DM, "Viral vaccines and their ways", Rev Infect Dis, 1, pp.502~516 (1979)
- Plotkin SA, "Immunologic properties of RA27-3 rubella virus vaccine: a comparison with strains presently licensed in the United States", JAMA, 225, pp.585~590 (1973)